Viatris VTRS
NASDAQ VTRS
$16.50 -0.11 (-0.66%)
As of: Sep 9, 2026 · 3:59 PM EDT

Viatris (VTRS) Depreciation & Amortization (CF) (2020 - 2026)

Viatris (VTRS) posted Depreciation & Amortization (CF) of $672.3 million for Q2 2026, down 0.56% on a QoQ basis from $676.1 million in Q1 2026, and down 0.88% year-over-year from $678.3 million in Q2 2025.

Analysis

Viatris (VTRS) Depreciation & Amortization (CF) (2020 - 2026) Analysis & Trends

Viatris has reported Depreciation & Amortization (CF) for 7 years, with the latest figure at $672.3 million in Q2 2026.

  • On a quarterly basis, Depreciation & Amortization (CF) fell 0.88% year-over-year to $672.3 million in Q2 2026; TTM through Jun 2026 was $2.8 billion, a 1.62% increase from a year earlier, with the FY2025 full-year figure at $2.8 billion, down 3.28% from the prior year.
  • Depreciation & Amortization (CF) was $672.3 million for Q2 2026 at Viatris, down from $676.1 million in the prior quarter.
  • The five-year high for Depreciation & Amortization (CF) was $869.8 million in Q4 2022, with the low at $644.4 million in Q4 2023.
  • Average Depreciation & Amortization (CF) over 5 years is $711.6 million, with a median of $689.8 million recorded in 2024.
  • The largest YoY upside for Depreciation & Amortization (CF) was 16.0% in 2022 against a maximum downside of 48.26% in 2022.
  • Over 5 years, Depreciation & Amortization (CF) stood at $869.8 million in 2022, then dropped by 25.91% to $644.4 million in 2023, then advanced by 15.8% to $746.2 million in 2024, then advanced by 2.76% to $766.8 million in 2025, then declined by 12.32% to $672.3 million in 2026.
  • The last three Depreciation & Amortization (CF) figures came in at $672.3 million (Q2 2026), $676.1 million (Q1 2026), and $766.8 million (Q4 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Depreciation & Amortization (Qtr)
1 Teva Pharmaceutical Industries 42.84 Bn 39.19 Bn 2.15 Bn 241.00 Mn
2 Viatris 19.13 Bn 18.24 Bn 1.46 Bn 672.30 Mn
3 Dr Reddys Laboratories 9.91 Bn 9.74 Bn 396.53 Mn 56.74 Mn
4 Amneal Pharmaceuticals 5.51 Bn 5.38 Bn 334.51 Mn -
5 Bausch Health Companies 2.30 Bn 464.50 Mn 2.10 Bn 281.00 Mn
6 Alvotech 1.50 Bn 1.36 Bn 2.56 Mn 10.33 Mn
7 Ani Pharmaceuticals 1.49 Bn 1.13 Bn 165.89 Mn 19.64 Mn
8 Amphastar Pharmaceuticals 1.00 Bn 714.13 Mn 93.47 Mn -
9 Fennec Pharmaceuticals 402.10 Mn 360.85 Mn 17.15 Mn -
10 RedHill Biopharma 178.35 Mn 178.35 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 672.30 Mn
Mar 31, 2026 676.10 Mn
Dec 31, 2025 766.80 Mn
Sep 30, 2025 688.50 Mn
Jun 30, 2025 678.30 Mn
Mar 31, 2025 664.70 Mn
Dec 31, 2024 746.20 Mn
Sep 30, 2024 669.70 Mn
Jun 30, 2024 786.30 Mn
Mar 31, 2024 691.00 Mn
Dec 31, 2023 644.40 Mn
Sep 30, 2023 679.40 Mn
Jun 30, 2023 686.70 Mn
Mar 31, 2023 730.00 Mn
Dec 31, 2022 869.80 Mn
Sep 30, 2022 699.50 Mn
Jun 30, 2022 722.30 Mn
Mar 31, 2022 736.00 Mn
Dec 31, 2021 749.80 Mn
Sep 30, 2021 1.02 Bn